Overview

* Integer Q3 2025 sales rose 8% to $468 mln, beating analysts' expectations

* Adjusted EPS for Q3 2025 increased 25% to $1.79, beating consensus

Outlook

* Integer expects 2025 sales between $1.840 bln and $1.854 bln

* Company anticipates 2025 adjusted EPS of $6.29 to $6.43

* Integer forecasts 2026 organic sales flat to up 4%

Result Drivers

* CARDIO & VASCULAR GROWTH - Sales increased 15% driven by new product ramps and acquisitions in electrophysiology and neurovascular

* NEUROMODULATION GROWTH - Growth driven by emerging neuromodulation customers with PMA products, offset by planned decline in spinal cord stimulation

* OTHER MARKETS DECLINE - Sales decreased 16% due to planned multi-year exit from portable medical market

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $468 mln $466.45

mln (9

Analysts

)

Q3 Beat $1.79 $1.67 (8

Adjusted Analysts

EPS )

Q3 Beat $63 mln $59.80

Adjusted mln (7

Net Analysts

Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Integer Holdings Corp ( ITGR ) is $137.50, about 21.5% above its October 21 closing price of $107.94

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)